BB Biotech AG (SW:BION) — Market Cap & Net Worth
Market Cap & Net Worth: BB Biotech AG (BION)
BB Biotech AG (SW:BION) has a market capitalization of $2.25 Billion (CHF1.78 Billion) as of May 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #5844 globally and #82 in its home market, demonstrating a -3.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BB Biotech AG's stock price CHF44.15 by its total outstanding shares 55149250 (55.15 Million). Analyse BION cash generation efficiency to see how efficiently the company converts income to cash.
BB Biotech AG Market Cap History: 2015 to 2026
BB Biotech AG's market capitalization history from 2015 to 2026. Data shows growth from $2.45 Billion to $3.08 Billion (3.20% CAGR).
BB Biotech AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BB Biotech AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
22.11x
BB Biotech AG's market cap is 22.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
32.52x
BB Biotech AG's market cap is 32.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.45 Billion | $659.23 Million | $652.82 Million | 3.71x | 3.75x |
| 2016 | $2.46 Billion | $-796.45 Million | -$802.07 Million | -3.08x | N/A |
| 2017 | $3.02 Billion | $693.05 Million | $687.50 Million | 4.36x | 4.40x |
| 2018 | $2.87 Billion | $-465.75 Million | -$471.34 Million | -6.16x | N/A |
| 2019 | $3.56 Billion | $685.24 Million | $677.43 Million | 5.19x | 5.25x |
| 2020 | $4.25 Billion | $699.23 Million | $691.17 Million | 6.07x | 6.14x |
| 2021 | $4.60 Billion | $-396.22 Million | -$404.81 Million | -11.61x | N/A |
| 2022 | $3.48 Billion | $-351.23 Million | -$357.81 Million | -9.92x | N/A |
| 2023 | $2.85 Billion | $35.00K | -$206.61 Million | 81546.08x | N/A |
| 2024 | $2.47 Billion | $111.63 Million | $75.90 Million | 22.11x | 32.52x |
Competitor Companies of BION by Market Capitalization
Companies near BB Biotech AG in the global market cap rankings as of May 4, 2026.
Key companies related to BB Biotech AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BB Biotech AG Historical Marketcap From 2015 to 2026
Between 2015 and today, BB Biotech AG's market cap moved from $2.45 Billion to $ 3.08 Billion, with a yearly change of 3.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF3.08 Billion | -1.78% |
| 2025 | CHF3.13 Billion | +26.98% |
| 2024 | CHF2.47 Billion | -13.52% |
| 2023 | CHF2.85 Billion | -18.05% |
| 2022 | CHF3.48 Billion | -24.29% |
| 2021 | CHF4.60 Billion | +8.36% |
| 2020 | CHF4.25 Billion | +19.31% |
| 2019 | CHF3.56 Billion | +23.97% |
| 2018 | CHF2.87 Billion | -5.11% |
| 2017 | CHF3.02 Billion | +23.14% |
| 2016 | CHF2.46 Billion | +0.33% |
| 2015 | CHF2.45 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BB Biotech AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Billion USD |
| MoneyControl | $2.25 Billion USD |
| MarketWatch | $2.25 Billion USD |
| marketcap.company | $2.25 Billion USD |
| Reuters | $2.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more